Inhibition of human ovarian tumor growth by cytokine-induced killer cells

Arch Pharm Res. 2007 Nov;30(11):1464-70. doi: 10.1007/BF02977372.


Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluated in vitro and in vivo. Although CD3+CD56+ cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cytokines / pharmacology*
  • Female
  • Humans
  • Immunotherapy, Adoptive*
  • Killer Cells, Natural / immunology*
  • Mice
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*


  • Cytokines